Nightstar Therapeutics plc (NITE)

25.47
0.03 0.12
NASDAQ : Health Technology
Prev Close 25.50
Open 25.50
Day Low/High 25.43 / 25.50
52 Wk Low/High 9.59 / 29.55
Volume 45.85K
Avg Volume 427.30K
Exchange NASDAQ
Shares Outstanding 33.48M
Market Cap 853.84M
EPS -1.30
Div & Yield N.A. (N.A)

Latest News

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Dow Tumbles as Rally Spurred by Trade Deal Hopes Fades

Dow Tumbles as Rally Spurred by Trade Deal Hopes Fades

Stocks recoup some losses in late trading but close lower as momentum from a report that China and the U.S. are in the final stages of completing a trade deal fades.

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Biogen will purchase Nightstar Therapeutics in an all-cash deal that values the British gene-therapy company at $877 million.

NITE Makes Bullish Cross Above Critical Moving Average

NITE Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Nightstar Therapeutics PLC crossed above their 200 day moving average of $15.89, changing hands as high as $16.50 per share. Nightstar Therapeutics PLC shares are currently trading up about 12% on the day.

RSI Alert: Nightstar Therapeutics (NITE) Now Oversold

RSI Alert: Nightstar Therapeutics (NITE) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

NITE Crosses Below Key Moving Average Level

NITE Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Nightstar Therapeutics PLC crossed below their 200 day moving average of $16.14, changing hands as low as $14.95 per share. Nightstar Therapeutics PLC shares are currently trading off about 11.3% on the day.

Notable Two Hundred Day Moving Average Cross - NITE

Notable Two Hundred Day Moving Average Cross - NITE

In trading on Thursday, shares of Nightstar Therapeutics PLC crossed below their 200 day moving average of $15.61, changing hands as low as $15.34 per share. Nightstar Therapeutics PLC shares are currently trading off about 5.2% on the day.

NITE Makes Bullish Cross Above Critical Moving Average

NITE Makes Bullish Cross Above Critical Moving Average

In trading on Thursday, shares of Nightstar Therapeutics PLC crossed above their 200 day moving average of $15.31, changing hands as high as $17.73 per share. Nightstar Therapeutics PLC shares are currently trading up about 17.5% on the day.

Nightstar Therapeutics Announces Initiation Of STAR Phase 3 Registrational Trial For NSR-REP1 In Choroideremia

Nightstar Therapeutics Announces Initiation Of STAR Phase 3 Registrational Trial For NSR-REP1 In Choroideremia

First-Ever Phase 3 Choroideremia Gene Therapy Trial

Nightstar Therapeutics Enters Oversold Territory (NITE)

Nightstar Therapeutics Enters Oversold Territory (NITE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Nightstar Announces Pricing Of Initial Public Offering

Nightstar Announces Pricing Of Initial Public Offering

Nightstar Therapeutics plc ("Nightstar" or the "Company"), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of its initial public offering in the...

Houlihan Lokey And Knight Form Joint Marketing Alliance

Houlihan Lokey, an international investment bank, today announced a joint marketing alliance with Knight Capital Group, Inc.

Technical Setups: News Corp., RBS

These stocks, including News Corp. and Royal Bank of Scotland, could be staging a technical move.

Growth Stocks, Market Movers, Google's China Challenge

Growth Stocks, Market Movers, Google's China Challenge

Guests include Matthew Buckley, TheStreet.com contributor and options specialist, Ken Shreve, TheStreet.com's Market Movers portfolio manager and Tim Holland, co-manager for the Aston/Tamro Capital Partners Fund.

E*Trade, TD Ameritrade Talk Has Skeptic

The chatter about a hookup between E*Trade and TD Ameritrade heated up again earlier this month, but Raymond James isn't buying it.

Sector Snap: New Ratings On Brokerages, Exchanges

Sector Snap: Goldman downgrades Jefferies, upgrades Nasdaq in update on financial sector

'Mad Money Lightning Round': Stick With ADC Telecom

'Mad Money Lightning Round': Stick With ADC Telecom

Cramer says he would be a buyer at under $6 a share.

Cramer's 'Mad Money' Recap: Next Week's Game Plan (Final)

Cramer's 'Mad Money' Recap: Next Week's Game Plan (Final)

Cramer lays out a strategy for investors to go bargain hunting during a holiday-shortened week.

Cramer's 'Mad Money' Follow-Up: Nov. 17

Cramer's 'Mad Money' Follow-Up: Nov. 17

Here's how some of Monday's 'Mad Money' stocks fared on Tuesday.

'Mad Money Lightning Round': Stay Away From Potash

'Mad Money Lightning Round': Stay Away From Potash

Cramer says he doesn't understand why the stock is up when the fundamentals are bad.

Cramer's 'Mad Money' Recap: The Bernanke Bounce (Final)

Cramer's 'Mad Money' Recap: The Bernanke Bounce (Final)

Cramer says the Fed chairman's speech today showed once again he knows what it takes to get the economy to recover.

Chairman Sells $6.5M Worth of Eastman Chemical

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.